معرفی
Pehr Lind, MD, PhD, Docent is an Associate Professor of Radiation Oncology at Karolinska Institutet, Stockholm, and leads the Radiation therapy / Radiation Oncology – Pehr Lind Group within the Department of Clinical Science and Education at Södersjukhuset. His research focuses on cutting-edge clinical radiotherapy for breast, prostate and rectal cancers, with a strong emphasis on organ-sparing techniques and artificial intelligence-driven optimisation from imaging to treatment delivery.
Education & Career
- PhD, Radiation Therapy in Breast Cancer, Karolinska Institutet (1999)
- Post-doctoral fellowship, Duke University, North Carolina, USA
- Associate Professor (Docent), Karolinska Institutet (2003–present)
- Adjunct Senior Lecturer, Department of Clinical Science and Education, Södersjukhuset, KI (2024)
- Affiliated Researcher, KI (2023–2028)
Research Interests
Dr Lind’s group integrates modern radiotherapy techniques with large-scale multicentre clinical trials. Core themes include:
- Organ-sparing chemoradiotherapy for early rectal cancer (STAR-TREC trial)
- AI-assisted planning and delivery optimisation across breast, prostate and rectal cancer
- Proton and advanced photon therapy comparisons
- Radiation-induced toxicities and secondary malignancies
- Biomarker-driven patient selection in gastric and pancreatic cancers
Scientific Output & Trends
With >150 peer-reviewed publications since 1999, his recent work (2020-2025) is dominated by high-impact phase II/III trials (STAR-TREC, CRITICS, ESPAC-4) and dosimetric/AI studies. The trajectory shows intensified focus on AI integration, proton therapy evaluation, and long-term toxicity modelling.
Grants & Funding
- AI in radiation therapy – Regional Cancercentrum Stockholm (2024-2025)
- STAR-TReC – Cancerfonden (2023-2027)
- STAR-TReC support – Region Stockholm (2023-2027)
- CITCCA ctDNA pilot – Swedish Research Council (2020)
Teaching & Mentorship
Dr Lind has successfully supervised five PhD students to graduation and remains actively involved in clinical and postgraduate education in radiation oncology and medical physics.
Collaborations & Networks
He coordinates multicentre studies across Sweden, the Netherlands, the UK and other European countries, working closely with academic centres and industry partners to accelerate translation of AI and proton therapy innovations into routine clinical practice.
